Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

AI-Powered heart patch could spot irregular rhythms at home

NCT ID NCT07188129

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested whether an artificial intelligence algorithm (ZywieAI) can accurately analyze heart rhythm data collected from a wearable sensor (ZywieZ3) worn for 24 hours. The sensor was placed in non-traditional positions on the chest. Researchers compared the AI's findings with assessments from cardiologists. The goal is to see if this technology can reliably detect conditions like atrial fibrillation, tachycardia, and other heart rhythm issues.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ZywieAI algorithm and ZywieZ3 wearable ECG sensor
What this could lead to
If successful, this could lead to a more convenient way to monitor heart rhythms at home using a wearable patch, potentially improving detection of arrhythmias.
What could go wrong
This is a small, completed device validation study, not a treatment trial. The algorithm may not perform as well in real-world settings or with diverse patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

153 people

The number who actually took part.

Started

Jan 2025

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Of the 150 subjects who complete the study, at least 60 (i.e., ≥ 40%) subjects must be male, and at least 60 (i.e., ≥ 40%) subjects must be female. * Subjects must be more than 18 years of age. * Subjects' body mass index (BMI) will be calculated based on their weight and height at the time of consent. BMI will be calculated using the CDC's online Adult BMI Calculator (https://www.cdc.gov/healthyweight/assessing/bmi/adult\_bmi/english\_bmi\_calculator/bmi\_calculator.html). This calculator will also automatically categorize the calculated BMI as underweight to healthy (\< 18.5 to 24.9), overweight (25.0 to 29.9), or obese (≥ 30.0). Of the 150 subjects who complete the study, no more than 70 subjects can be from a given BMI category. * Subjects must be able to read, write, and understand English. * Subjects must be in good general health (i.e., no current or recent severe illness). * Subjects must have a known condition of Atrial Fibrillation (AF), Tachycardia, Bradycardia, Premature Ventricular Contractions (PVC/VEB), and/or Premature Atrial Contractions (PAC) diagnosed by a medical professional. * Subjects with body hair on their upper-left chest must be willing to have the body hair clipped by a Testing Facility analyst before applying the Test Device. * Subjects must be willing to have their upper-left chest cleaned with 70% isopropanol preparation pads before applying the Test Device. Exclusion Criteria: * Subjects cannot be currently participating in another clinical study. * Subjects cannot have active skin rashes, dermatoses, or breaks in the skin on the upper left chest region. * Subjects cannot have undergone any surgeries during the last 3 months involving incisions along their upper-left chest. * Subjects cannot have any tattoos on their upper-left chest. * Subjects cannot have currently active inflammatory skin conditions (e.g., atopic dermatitis/eczema, contact dermatitis, or psoriasis) anywhere on the body within 2 days of the start of the test period and during the 24-hour test period. * Subjects cannot have a medical diagnosis of an organ transplant, medicated or uncontrolled diabetes, hepatitis B, hepatitis C, an immunocompromised condition such as AIDS (or HIV positive), lupus, medicated fibromyalgia, ulcerative colitis, Crohn's disease, moderate to severe asthma (requiring daily use of medication), or medicated multiple sclerosis. * Subjects cannot have a pacemaker. * Subjects cannot have any type of port, shunt, or Peripherally Inserted Central Catheter (PICC). * Subjects cannot receive any vaccinations within 7 days of the start of the test period and while participating in the 24-hour test period. * Subjects cannot have known allergies or sensitivities to latex (natural rubber), adhesives, inks, sunscreens, deodorants, laundry detergents, cleansers, soaps, lotions, to topical application of fragrances (e.g., perfumes or colognes), acrylic, hydrogel, isopropyl alcohol, C11-12 isoparaffin, isopropyl palmitate, isopropyl myristate, or isopropyl stearate. * Subjects cannot be pregnant, plan to become pregnant, or cause a partner to become pregnant during the study. * Subjects cannot be nursing a child during the 24-hour test period. * Subjects cannot have any medical condition or use any medications that, in the opinion of the Principal Investigator or Consulting Physicians, should preclude participation or might impact data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation Atrial Premature Complexes Bradycardia Tachycardia Ventricular Premature Complexes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bioscience of Bozeman, LLC

    Bozeman, Montana, 59715, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.